keyword
MENU ▼
Read by QxMD icon Read
search

neutropenic fever

keyword
https://www.readbyqxmd.com/read/29910543/clinicohematological-profile-of-febrile-neutropenia-in-childhood-acute-leukemia-and-utility-of-serum-procalcitonin-levels-in-neutropenic-patients
#1
Rajan Kapoor, Ashish K Simalti, Shuvendu Roy, Pulkit Agarwal
Introduction: This study was planned to explore the clinical and hematological profile of febrile neutropenia (FN) in Indian children with focus on correlation of degree of neutropenia with fever and procalcitonin (PCT) level and the utility of serum PCT levels in cases of FN. Materials and Methods: Children below 12 years, receiving chemotherapy for hematological malignancy having oral temperature more than 100°F and absolute neutrophil count (ANC) below 500/mm3 were included...
May 2018: Indian Journal of Critical Care Medicine
https://www.readbyqxmd.com/read/29889152/pulmonary-infectious-complications-after-hematopoietic-stem-cell-transplantation-a-practical-guide-to-clinicians
#2
Juan Gea-Banacloche
PURPOSE OF REVIEW: The current review highlights the most relevant articles on lung infections following hematopoietic stem cell transplantation (HCT) published over the last year. Between 30 and 50% of HCT recipients will develop pulmonary infiltrates. These pulmonary complications may be infectious (caused by virus, bacteria, fungi, or protozoa) or noninfectious (e.g., fluid overload, heart failure, transfusion reactions like transfusion associated lung injury and transfusion-associated circulatory overload, drug reactions, engraftment syndrome, idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, cryptogenic organizing pneumonia, and bronchiolitis obliterans syndrome)...
June 7, 2018: Current Opinion in Organ Transplantation
https://www.readbyqxmd.com/read/29880613/real-world-outcomes-and-management-strategies-for-venetoclax-treated-chronic-lymphocytic-leukemia-patients-in-the-united-states
#3
Anthony R Mato, Meghan Thompson, John N Allan, Danielle M Brander, John M Pagel, Chaitra S Ujjani, Brian T Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P Skarbnik, Jeffrey J Pu, Paul M Barr, Alison R Sehgal, Bruce D Cheson, Clive S Zent, Hande H Tuncer, Stephen J Schuster, Peter V Pickens, Nirav N Shah, Andre Goy, Allison M Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M Gashonia, Arun K Singavi, Lindsey E Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R Furman, Chadi Nabhan
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with CLL treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated IGHV, 45% del(17p), and 26...
June 7, 2018: Haematologica
https://www.readbyqxmd.com/read/29869680/reduced-dose-pegfilgrastim-is-associated-with-less-bone-pain-without-increased-neutropenia-a-retrospective-study
#4
Elyse E Lower, Mahmoud Charif, Meg Bartelt
BACKGROUND: Chemotherapy for breast cancer is associated with a high risk of neutropenia. Pegfilgrastim reduces the risk of neutropenic fever but commonly causes bone pain. OBJECTIVE: Evaluate whether a reduced dose of pegfilgrastim (3 mg) reduced the frequency of bone pain without compromising efficacy. METHODS: Records reviewed from breast cancer patients who received at least one 3 mg dose of pegfilgrastim, white blood count (WBC), and absolute granulocyte counts (AGC) were collected...
June 5, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29866872/primary-fungal-prophylaxis-in-hematological-malignancy-a-network-meta-analysis-of-randomized-controlled-trials
#5
Cho-Hao Lee, Chin Lin, Ching-Liang Ho, Jung-Chung Lin
Several new anti-fungal agents have become available for primary fungal prophylaxis of neutropenia fever in haematological malignancy patients. Our aim was to synthesize all evidence on efficacy and enable an integrated comparison of all current treatments.We performed a systematic literature review to identify all publicly available evidence from randomized controlled trials (RCT). We searched Embase, PubMed, the Cochrane Central Register of Controlled Clinical Trials, and the website www.ClinicalTrials.gov In total, 54 RCTs were identified, including 13 treatment options...
June 4, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29765225/increased-risk-of-adverse-drug-events-secondary-to-bevacizumab-treatment-in-patients-with-advanced-or-metastatic-breast-cancer-a-meta-analysis-of-randomized-controlled-trials
#6
Sooyoung Shin, Yoojin Noh
Background: Several clinical trials have shown an increased risk of hypertension with bevacizumab when added to chemotherapy in different types of malignancy; however, the risks of other significant adverse events besides hypertension, specifically in breast cancer, have not been completely elucidated. This study was conducted with the aim, primarily, to assess the overall incidence and risk of common toxicities associated with bevacizumab in patients with advanced or metastatic breast cancer and, secondarily, to descriptively review study results concerning a potential correlation between bevacizumab-induced hypertension and its efficacy for breast cancer treatment...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29748010/canadian-cancer-trials-group-cctg-ind211-a-randomized-trial-of-pelareorep-reolysin-in-patients-with-previously-treated-advanced-or-metastatic-non-small-cell-lung-cancer-receiving-standard-salvage-therapy
#7
Penelope A Bradbury, Donald G Morris, Garth Nicholas, Dongsheng Tu, Moustapha Tehfe, John R Goffin, Frances A Shepherd, Richard W Gregg, Jeffrey Rothenstein, Christoper Lee, Sara Kuruvilla, Bruce D Keith, Vamsee Torri, Normand Blais, Desiree Hao, Grzegorz J Korpanty, Glenwood Goss, Barbara L Melosky, Mihaela Mates, Natasha Leighl, Jean-Pierre Ayoub, Joana Sederias, Harriet Feilotter, Lesley Seymour, Scott A Laurie
OBJECTIVES: Pelareorep (reolysin), a Dearing strain of reovirus serotype 3, has demonstrated oncolytic activity as single agent and synergy with chemotherapy. We evaluated pelareorep, combined with standard second-line chemotherapy in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: This randomized phase II trial enrolled patients with advanced or metastatic NSCLC after first line chemotherapy. After a safety run-in, patients were randomized 1:1 to chemotherapy (pemetrexed [500 mg/m2, non-squamous], or docetaxel [75 mg/m2], day 1 every 21 days]) +/- pelareorep (4...
June 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29746702/a-patient-with-neutropenic-fever-and-intraosseous-gas
#8
Bruno Ali Lopez Luis, Francisco Javier Antiga-López, Edgar Ortiz-Brizuela
No abstract text is available yet for this article.
May 8, 2018: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/29725528/-blastoid-variant-of-burkitt-lymphoma-with-additional-partial-1q-tetrasomy
#9
Ahsan Siddiqi, Sheshadri Madhusudhana, Alexey Glazyrin
Burkitt lymphoma is cytogenetically characterized by t(8;14)(q24;q32) translocation, sometimes accompanied by additional cytogenetic abnormalities. These abnormalities usually result in more aggressive clinical presentation and morphology of the disease. The current report presens a case of Burkitt lymphoma with t(8;14)(q24;q32) accompanied by partial tetrasomy of chromosome 1(47,XY,+1,i(1)(q10),t(8;14)(q24;q32)[2]/46,XY[18]). The patient was a 59-year-old male who presented with abdominal pain, leukocytosis and tumor lysis syndrome...
May 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29724214/multiple-challenges-of-antibiotic-use-in-a-large-hospital-in-ethiopia-a-ward-specific-study-showing-high-rates-of-hospital-acquired-infections-and-ineffective-prophylaxis
#10
Girma Gutema, Helle Håkonsen, Ephrem Engidawork, Else-Lydia Toverud
BACKGROUND: This project aims to study the use of antibiotics in three clinical wards in the largest tertiary teaching hospital in Ethiopia for a period of 1 year. The specific aims were to assess the prevalence of patients on antibiotics, quantify the antibiotic consumption and identify the main indications of use. METHOD: The material was all the medical charts (n = 2231) retrieved from three clinical wards (internal medicine, gynecology/obstetrics and surgery) in Tikur Anbessa Specialized Hospital (TASH) in Addis Ababa between September 2013 and September 2014...
May 3, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29723393/phase-2-trial-of-bortezomib-in-combination-with-rituximab-plus-hyperfractionated-cyclophosphamide-vincristine-doxorubicin-and-dexamethasone-alternating-with-bortezomib-rituximab-methotrexate-and-cytarabine-for-untreated-mantle-cell-lymphoma
#11
Jorge E Romaguera, Michael Wang, Lei Feng, Luis E Fayad, Frederick Hagemeister, Peter McLaughlin, M Alma Rodriguez, Michelle Fanale, Robert Orlowski, Larry W Kwak, Sattva Neelapu, Yasuhiro Oki, Barbara Pro, Anas Younes, Felipe Samaniego, Nathan Fowler, Kimberly Hartig, Marisa Valentinetti, Judy Smith, Peggy Ford, Adam Naig, L Jeffrey Medeiros, Hagop M Kantarjian, Andre Goy
BACKGROUND: Although the outcomes of patients with mantle cell lymphoma (MCL) have improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory MCL and has shown additive and/or synergistic effects in preclinical trials with known effective agents. METHODS: This is a report of a prospective phase 2 trial of bortezomib added to rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR-hyperCVAD)/rituximab, high-dose methotrexate, and high-dose cytarabine (BzR-MA) for 95 patients with newly diagnosed MCL...
May 3, 2018: Cancer
https://www.readbyqxmd.com/read/29722200/emergency-department-presentations-in-early-stage-breast-cancer-patients-receiving-adjuvant-and-neoadjuvant-chemotherapy
#12
Monica Tang, Patrick Horsley, Craig R Lewis
(Neo)adjuvant chemotherapy for early stage breast cancer is associated with side-effects, resulting in increased emergency department (ED) presentations. Treatment-related toxicity can affect quality of life, compromise chemotherapy delivery and treatment outcomes, and increase healthcare use. We performed a retrospective study of ED presentations in patients receiving curative chemotherapy for early breast cancer to identify factors contributing to ED presentations. Of 102 patients, 39 (38%) presented to ED within 30 days of chemotherapy, resulting in 63 ED presentations in total...
May 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29687743/clinical-outcomes-of-treatment-with-filgrastim-versus-a-filgrastim-biosimilar-and-febrile-neutropenia-associated-costs-among-patients-with-nonmyeloid-cancer-undergoing-chemotherapy
#13
Lee S Schwartzberg, Lincy S Lal, Sanjeev Balu, Kim Campbell, Lee Brekke, Andrew DeLeon, Caitlin Elliott, Stephanie Korrer
BACKGROUND: Granulocyte colony-stimulating factors such as filgrastim are used to decrease the incidence of febrile neutropenia (FN) among patients with nonmyeloid cancers undergoing chemotherapy treatment. Although the biosimilar filgrastim-sndz has been approved in the United States since 2015, limited real-world comparisons of filgrastim-sndz versus reference filgrastim (filgrastim-ref) have been conducted. OBJECTIVE: To compare FN incidence and assess overall FN-related health care resource utilization and medical costs among U...
April 24, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29616457/presepsin-as-a-diagnostic-marker-of-bacterial-infections-in-febrile-neutropenic-pediatric-patients-with-hematological-malignancies
#14
Ahmad Baraka, Marwa Zakaria
Febrile neutropenia (FN) is often observed in hematological malignancies (HEM). Presepsin is also known as soluble CD14 subtype; it is a glycoprotein fragment derived from monocytes and macrophages. We aimed to evaluate the significance of presepsin and other biomarkers for diagnosis of bacteremia in children with HEM. Sixty pediatric patients with different HEM (acute lymphoblastic leukemia 36, acute myeloid leukemia 12, non-Hodgkin lymphoma 10, and Hodgkin disease 2). Thirty age and sex-matched healthy children serving as control were enrolled in this study...
April 3, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29608680/extended-versus-bolus-infusion-of-broad-spectrum-%C3%AE-lactams-for-febrile-neutropenia-an-unblinded-randomized-trial
#15
Ron Ram, Yael Halavy, Odelia Amit, Yael Paran, Eugene Katchman, Bruria Yachini, Svetlana Kor, Irit Avivi, Ronen Ben-Ami
Background: Febrile neutropenia may be a sign of severe infection, and is associated with significant morbidity and mortality in high-risk patients with hematologic malignancies. Extended infusion of β-lactam antibiotics is associated with greater clinical response than is bolus infusion in non-neutropenic critically ill patients, but data are lacking for febrile neutropenic patients. Methods: We designed a single-center, non-blinded randomized trial comparing extended infusion (4 hours) and bolus infusion (30 minutes) of piperacillin-tazobactam or ceftazidime in high-risk patients with febrile neutropenia...
March 28, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29589346/-recommendations-for-diagnostics-and-therapy-of-children-with-cancer-presenting-with-fever-and-neutropenia-comparison-of-two-current-guidelines
#16
Thomas Lehrnbecher, Andreas Groll, Philipp Agyeman, Roland A Ammann, Andishe Attarbaschi, Uta Behrends, Christoph Berger, Axel Hamprecht, Markus Hufnagel, Hans-Jürgen Laws, Max Scheler, Christian Temme, Simon Vieth, Arne Simon
Immunocompromised children and adolescents receiving treatment for cancer have a considerably increased risk for infection. Neutropenia is the most important single risk factor for infectious complications, and fever in neutropenia is considered as an emergency. Whereas guidelines for the management of fever in neutropenic adults have been established for decades, specific pediatric guidelines have not been developed until recently. As children differ in many aspects from adults such as in the underlying malignancy or in the availability and dosing of antimicrobial compounds, guidelines for pediatric patients are important...
April 2018: Klinische Pädiatrie
https://www.readbyqxmd.com/read/29564621/addition-of-doxycycline-to-ciprofloxacin-for-infection-prophylaxis-during-autologous-stem-cell-transplants-for-multiple-myeloma
#17
J M Sivik, J Davidson, C M Hale, J J Drabick, G Talamo
BACKGROUND: The most commonly used antibacterial prophylaxis during autologous stem cell transplants (ASCT) for multiple myeloma (MM) involves a fluoroquinolone, such as ciprofloxacin or levofloxacin. We assessed the impact of adding doxycycline to ciprofloxacin as routine antibacterial prophylaxis in these patients. METHODS: We retrospectively reviewed electronic medical records and our ASCT database to analyze rates and types of bacterial infections in MM patients who underwent ASCT in our institution...
March 21, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29550383/liposomal-grb2-antisense-oligodeoxynucleotide-bp1001-in-patients-with-refractory-or-relapsed-haematological-malignancies-a-single-centre-open-label-dose-escalation-phase-1-1b-trial
#18
Maro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, Naveen Pemmaraju, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Michael Andreeff, Marina Konopleva, Miranda Lim, Sherry Pierce, Susan O'Brien, Yesid Alvarado, Srdan Verstovsek, William Wierda, Hagop Kantarjian, Jorge Cortes
BACKGROUND: Activating mutations of tyrosine kinases are common in leukaemias. Oncogenic tyrosine kinases use the growth factor receptor-bound protein 2 (Grb2) for signal transduction, leading to activation of mitogen-activated protein kinase (MAPK) 1 and MAPK3 (ERK2 and ERK1). We hypothesised that inhibition of Grb2 would suppress ERK1 and ERK2 activation and inhibit leukaemia progression. To inhibit Grb2, a liposome-incorporated antisense oligodeoxynucleotide that blocks Grb2 protein expression, BP1001, was developed...
April 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29531929/determination-relation-of-the-zinc-serum-level-in-acute-leukemia-adult-patients-with-mucositis-and-neutropenic-prevalence-before-and-after-treatment-in-isfahan-seyed-al-shohada-hospital-2012-2013
#19
Valiollah Mehrzad, Mehdi Mahmood-Zadeh, Awat Feizi, Arash Raisi
Background: Neutropenic fever and mucositis with 70% outbreak average is one of the major reasons of death in the acute leukemia adult patients. The aim of this study was to determine the relationship of serum zinc level with neutropenic fever and mucositis prevalence in acute leukemia adult patients and comparison of the effects of therapeutic intervention with the serum zinc correct level in the group of patients with zinc deficiency. Materials and Methods: From May 2012 to May 2013 in a double-blind, randomized, placebo-controlled study, on the basis of zinc serum level, 40 acute leukemia adult patients were divided into two groups of normal and deficiency zinc, and neutropenic fever and mucositis prevalence were taken into consideration in each and every group...
2018: Advanced Biomedical Research
https://www.readbyqxmd.com/read/29512471/tc-0-05-as-a-pharmacokinetic-parameter-of-paclitaxel-for-therapeutic-efficacy-and-toxicity-in-cancer-patients
#20
D S Xin, L Zhou, C Z Li, S Q Zhang, H Q Huang, G D Qiu, L F Lin, Y Q She, J T Zheng, C Chen, L Fang, Zhe-Sheng Chen, S Y Zhang
BACKGROUND: Paclitaxel (PTX) has remarkable anti-tumor activity, but it causes severe toxicities. There is an urgent need to seek an appropriate pharmacokinetic parameter of PTX to improve treatment efficacy and reduce adverse effects. OBJECTIVE: To evaluate the association of pharmacokinetic parameter TC>0.05 of paclitaxel (PTX) and its therapeutic efficacy and toxicity in patients with solid tumors. METHOD: A total of 295 patients with ovarian cancer, esophageal cancer, breast cancer, and non-small cell lung cancer (NSCLC), who were admitted to the Tumor Hospital of Shantou University Medical College, China, were recruited for this study...
March 5, 2018: Recent Patents on Anti-cancer Drug Discovery
keyword
keyword
45469
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"